Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).

Abstract

It had been previously shown that patients who receive neoadjuvant systemic therapy (NST) are more likely to undergo breast-conserving therapy (BCT) than those who have primary surgery. However, the frequency with which patients who are not BCT-eligible prior to NST convert to BCT-eligible with treatment is unknown. To document this conversion rate in a subset of patients expected to have a high clinical response rate to NST, we studied surgical assessment and management of patients enrolled on a randomized neoadjuvant trial for stage II-III HER2-positive breast cancer (HER2+BC)(CALGB 40601). The treating surgeon assessed BCT candidacy based on clinico-radiographic criteria both before and after NST. Definitive breast surgical management was at surgeon and patient discretion. We sought to determine (1) the conversion rate from BCT-ineligible to BCT-eligible (2) the percentage of BCT-eligible patients who chose breast conservation, and (3) the rate of successful BCT. We also evaluated surgeon-determined factors for BCT-ineligibility and the correlation between BCT eligibility and pathologic complete response (pCR). Of 292 patients with pre- and post-NST surgical assessments, 59% were non-BCT candidates at baseline. Of the 43% of these patients who converted with NST, 67% opted for BCT, with an 80% success rate. NST increased the BCT-eligible rate from 41 to 64%. Common factors cited for BCT-ineligibility prior to NST including tumor size (56%) and probable poor cosmetic outcome (26%) were reduced by 67 and 75%, respectively, with treatment, while multicentricity, the second most common factor (33%), fell by only 16%. Since 23% of the BCT-eligible patients chose mastectomy, BCT was the final surgical procedure in just 40% of the patients. Patients considered BCT-eligible both at baseline and after NST had a pCR rate of 55%, while patients who were BCT-ineligible prior to NST had the same pCR rate (44%) whether they converted to BCT-eligible or not. Many patients with HER2+BC deemed ineligible for BCT at baseline can be converted to BCT-eligible with NST; excluding patients with multicentric disease substantially increases that percentage. In converted patients who opt for BCT, the success rate is similar to that of patients considered BCT-eligible at baseline. Whether a BCT-ineligible patient converts to BCT eligibility or not does not appear to affect the likelihood of achieving a pCR. Despite the efficacy of NST in this patient cohort, only 40% of patients had successful BCT; further research into why BCT-eligible patients often opt for mastectomy is needed.